|
Researchers safely regenerate failing mouse hearts with programmed embryonic stem cells
February 28, 2007ROCHESTER, Minn. — Mayo Clinic researchers have safely transplanted cardiac preprogrammed embryonic stem cells into diseased hearts of mice successfully regenerating infarcted heart muscle without precipitating the growth of a cancerous tumor — which, so far, has impeded successful translation into practice of embryonic stem cell research.
The Mayo study is the first known report establishing a successful, tumor-resistant approach to growing new heart tissue from an embryonic stem cell source. The study is published in the February issue of the Journal of Experimental Medicine.
Embryonic stem cells have the potential to become any cell type in the body. But directing the stem cells to regenerate targeted tissue is a process that hasn't yet been perfected. Scientists continue to closely scrutinize stem cell strategies to establish even safer and more effective treatments for disease.
"Embryonic stem cells are like a stealth fighter jet that flies virtually undetectable by radar," says the study's first author, Atta Behfar, M.D., Ph.D., a clinician-investigator fellow in the Mayo Graduate School of Medicine. "The host body doesn't recognize embryonic stem cells, which it allows to multiply freely in an unimpeded fashion."
The Mayo study is the first known report of a successful strategy for programming embryonic stem cells to suppress cancer genes, to mature into heart cells (also known as cardiomyocytes) and to successfully fix injured hearts without causing tumors to develop. The study removes a critical obstacle towards translation of regenerative technology into developing new therapies for people with heart disease.
"Embryonic stem cells have an unequaled potential for repair, yet it has been uncertain whether we can drive them to safely regenerate the tissue we would like to replace," says Andre Terzic, M.D., Ph.D., a stem cell specialist and lead investigator of the study. "Our objective was to repair heart muscle by avoiding the limitations intrinsic to embryonic stem cells, i.e., potential tumor growth.
"In this study, we have successfully programmed embryonic stem cells to safely generate new cardiac muscle tissue, leading potentially to new therapy," Dr. Terzic says.
The Study
Researchers transplanted mouse embryonic stem cells into infarcted hearts of mice. Consistent with the risk for uncontrolled growth, a significant number of recipient mouse hearts developed tumors. To avoid tumor formation, researchers secured guided differentiation of stem cells to produce cardiopoietic cells, or cardiac specified cell precursors rather than any cell type. Treatment with cardiopoietic cells proved to have no tendency to develop into cancer. Tumor-free heart repair occurred in all treated mice. Two months after cardiopoietic stem cell transplantation, scientists reported a 35 percent improved output in treated hearts.
The threat of tumor growth associated with embryonic stem cell transplants was eliminated by restricting expression of oncogenes and pluripotency genes through transgenic manipulation of tumor necrosis factor alpha (TNFa), a genome reprogramming protein. Researchers found that over-expressed TNFa promoted guided control of cardiac embryonic stem cells to drive the cardiogenesis process.
Researchers discovered approximately 15 proteins whose production was dramatically increased after TNFa stimulation. These proteins, when combined into a "cocktail," secured guided differentiation of embryonic stem cells, producing cardiac progenitors called cardiopoietic cells. Such guided heart precursor cells did not form tumors, even though they were transplanted at doses that would otherwise carry a high risk for tumorigenesis with embryonic stem cells.
"Our goal is to apply these findings to adult stem cells, and in our next step create the first human cardioprogenitor stem cells as a tool for therapies in the future," Dr. Terzic says.
Mayo Clinic
"Embryonic stem cells are like a stealth fighter jet that flies virtually undetectable by radar," says the study's first author, Atta Behfar, M.D., Ph.D., a clinician-investigator fellow in the Mayo Graduate School of Medicine. "The host body doesn't recognize embryonic stem cells, which it allows to multiply freely in an unimpeded fashion."
The Mayo study is the first known report of a successful strategy for programming embryonic stem cells to suppress cancer genes, to mature into heart cells (also known as cardiomyocytes) and to successfully fix injured hearts without causing tumors to develop. The study removes a critical obstacle towards translation of regenerative technology into developing new therapies for people with heart disease.
"Embryonic stem cells have an unequaled potential for repair, yet it has been uncertain whether we can drive them to safely regenerate the tissue we would like to replace," says Andre Terzic, M.D., Ph.D., a stem cell specialist and lead investigator of the study. "Our objective was to repair heart muscle by avoiding the limitations intrinsic to embryonic stem cells, i.e., potential tumor growth.
"In this study, we have successfully programmed embryonic stem cells to safely generate new cardiac muscle tissue, leading potentially to new therapy," Dr. Terzic says.
The Study
Researchers transplanted mouse embryonic stem cells into infarcted hearts of mice. Consistent with the risk for uncontrolled growth, a significant number of recipient mouse hearts developed tumors. To avoid tumor formation, researchers secured guided differentiation of stem cells to produce cardiopoietic cells, or cardiac specified cell precursors rather than any cell type. Treatment with cardiopoietic cells proved to have no tendency to develop into cancer. Tumor-free heart repair occurred in all treated mice. Two months after cardiopoietic stem cell transplantation, scientists reported a 35 percent improved output in treated hearts.
The threat of tumor growth associated with embryonic stem cell transplants was eliminated by restricting expression of oncogenes and pluripotency genes through transgenic manipulation of tumor necrosis factor alpha (TNFa), a genome reprogramming protein. Researchers found that over-expressed TNFa promoted guided control of cardiac embryonic stem cells to drive the cardiogenesis process.
Researchers discovered approximately 15 proteins whose production was dramatically increased after TNFa stimulation. These proteins, when combined into a "cocktail," secured guided differentiation of embryonic stem cells, producing cardiac progenitors called cardiopoietic cells. Such guided heart precursor cells did not form tumors, even though they were transplanted at doses that would otherwise carry a high risk for tumorigenesis with embryonic stem cells.
"Our goal is to apply these findings to adult stem cells, and in our next step create the first human cardioprogenitor stem cells as a tool for therapies in the future," Dr. Terzic says.
Mayo Clinic
Stem Cells News and Current Stem Cells Events RSSSmall protein may have big role in making more bone and less fat
A small protein may have a big role in helping you make more bone and less fat, researchers say.
Researchers link early stem cell mutation to autism
In a breakthrough scientific study published today in the Proceedings of the National Academy of Sciences, scientists at the Burnham Institute for Medical Research have shown that neural stem cell development may be linked to Autism.
How to build a plant
Walking through a tropical or temperate forest immediately impresses us with the myriad forms and soaring structures of the plant world, but our knowledge of how plants are actually built, cell by cell, is still incomplete.
Nerve cells derived from stem cells and transplanted into mice may lead to improved brain treatments
Scientists at the Burnham Institute for Medical Research have, for the first time, genetically programmed embryonic stem (ES) cells to become nerve cells when transplanted into the brain, according to a study published today in The Journal of Neuroscience.
New source of heart stem cells discovered
Researchers at Children's Hospital Boston are continuing to document the heart's earliest origins. Now, they have pinpointed a new, previously unrecognized group of stem cells that give rise to cardiomyocytes, or heart muscle cells.
Penn researchers find key developmental pathway activates lung stem cells
Researchers from the University of Pennsylvania School of Medicine found that the activation of a molecular pathway important in stem cell and developmental biology leads to an increase in lung stem cells. Harnessing this knowledge could help develop therapies for lung-tissue repair after injury or disease.
Ability to track stem cells in tumors could advance cancer treatments
Using noninvasive molecular imaging technology, a method has been developed to track the location and activity of mesenchymal stem cells (MSCs) in the tumors of living organisms.
Wealth of genomic hotspots discovered in embryonic stem cells
In a paper published in Cell on June 13, 2008, Singapore scientists at the Genome Institute of Singapore (GIS) and the National University of Singapore (NUS) unveil an atlas that showing the location of "genomic hotspots" of essential protein "switches" (transcription factors) that are critical for maintaining the embryonic stem (ES) cell state.
'HiCy' drug regimen reverses ms symptoms in selected patients
A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and may even restore neurological function lost to the disease, Johns Hopkins researchers report.
Human stem cells show promise against fatal children's diseases
Scientists have used human stem cells to dramatically improve the condition of mice with a neurological condition similar to a set of diseases in children that are invariably fatal, according to an article in the June issue of the journal Cell Stem Cell.
More Stem Cells News Articles
 | My Sister's Keeper: A Novel by Jodi Picoult |
 | Embryo: A Defense of Human Life by Robert P. George, Christopher Tollefsen |
 | The Oxygen Revolution: Hyperbaric Oxygen Therapy: The Groundbreaking New Treatment for Stroke, Alzheimer's, Parkinson's, Arthritis, Autism, Learning Disabilities and More by Paul G. Harch, Virginia Mccullough |
 | Irreparable Harm by Randy D. Singer |
 | The Proteus Effect: Stem Cells and Their Promise for Medicine by Ann B. Parson |
 | Miracle Stem Cell Heart Repair: (For Heart Attack, Heart Failure and Bypass Patients) by Christian Wilde |
 | Umbilical Cord Stem Cell Therapy: The Gift of Healing from Healthy Newborns by David A. Steenblock, Anthony G., Ph.D. Payne |
 | Cell of Cells: The Global Race to Capture and Control the Stem Cell by Cynthia Fox |
 | Sex, Science, and Stem Cells by Diana DeGette |
 | The Stem Cell Divide: The Facts, the Fiction, and the Fear Driving the Greatest Scientific, Political, and Religious Debate of Our Time by Michael Bellomo |
| © 2008 BrightSurf.com |